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Background: Because latent Epstein Barr (EBV)-infection is a specific characteristic of malignant nasopharyngeal
carcinoma (NPC), various molecules of viral origin are obvious candidate biomarkers in this disease. In a previous
study, we could show in a few clinical samples that it was possible to detect a category of EBV microRNAs called
miR-BARTs in the plasma of at least a fraction of NPC patients. The first aim of the present study was to investigate
the status of circulating miR-BART17-5p (one of the miR-BARTs hereafter called miR-BART17) and EBV DNA in a
larger series of NPC plasma samples. The second aim was to determine whether or not circulating miR-BART17
was carried by plasma exosomes.
Patients and methods: Plasma samples were collected from 26 NPC patients and 10 control donors, including
9 patients with non-NPC Head and Neck squamous cell carcinoma and one healthy EBV carrier. Concentrations of
miR-BART17 and two cellular microRNAs (hsa-miR-16 and -146a) were assessed by real-time quantitative PCR with
spike-in normalization and absolute quantification. In addition, for 2 patients, exosome distributions of miR-BART17
and miR-16 were investigated following plasma lipoprotein fractionation by isopycnic density gradient
ultrcentrifugation.
Results: The miR-BART17 was significantly more abundant in plasma samples from NPC patients compared to
non-NPC donors. Above a threshold of 506 copies/mL, detection of miR-BART17 was highly specific for NPC
patients (ROC curve analysis: AUC=0.87 with true positive rate = 0.77, false positive rate = 0.10). In this relatively
small series, the concentration of plasma miR-BART17 and the plasma EBV DNA load were not correlated. When
plasma samples were fractionated, miR-BART17 co-purified with a protein-rich fraction but not with exosomes.
Conclusions: Detection of high concentrations of plasma miR-BART17 is consistent in NPC patients. This parameter
is, at least in part, independent of the viral DNA load. Circulating miR-BART17 does not co-purify with exosomes.
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Nasopharyngeal carcinoma (NPC) is a tumor arising
from the epithelium lining the upper part of the pharynx
behind the nasal cavities. Its incidence is very high in
some highly populated regions of the world, especially
Southeast Asia and North Africa [1]. This disease is re-
sponsible for the death of 50 000 people each year and
hundred others suffer from the consequences of radio-
therapy and chemotherapy. Therefore, in these coun-
tries, NPC is a major public health problem. In addition,
NPC has become relatively frequent in some places of
Europe and North America due to large numbers of over-
sea immigrants from endemic regions. Major issues to
optimize the treatment of this disease are first, to lessen
the rate of advanced disease at diagnosis by improving
screening tools and policies, secondly, to personalize the
treatment and follow up by identifying prognostic or pre-
dictive biomarkers.
One remarkable particularity of this disease is its con-
stant association with the Epstein-Barr virus. EBV is one
etiological factor of NPC which acts in combination with
some forms of genetic susceptibility and/or environmen-
tal aggressions. The EBV genome is present in the nuclei
of all malignant cells which are in their overwhelming
majority latently infected. Despite the absence of viral
replication, several viral genes are active in latently
infected cells, driving production of a few viral proteins
and non coding RNAs, including viral microRNAs. In
EBV-infected cells, depending on the host cell back-
ground, EBV microRNAs can be transcribed from 3 clus-
ters of viral genes, one located in the BamH1-H region
(the BHRF1 cluster) and two located in the BamH1-A re-
gion (the BART clusters). In most NPC tumors, the BART
clusters are transcribed at a very high level whereas the
BHRF1 cluster is silent [2-5].
In a previous report, we have shown that BART
miRNAs are secreted by NPC cells in vitro and are select-
ively detected in plasma samples from mice xenografted
with NPC tumors but not in plasma samples from mice
xenografted with non-NPC, EBV-negative tumors [6]. We
have also reported the detection of miR-BART7 in a small
series of plasma samples from NPC patients. These data
suggested that circulating BART microRNAs could be-
come a novel source of viral biomarkers for NPC popula-
tion screening and patient monitoring. However, in this
small set of patients, the average concentration of miR-
BART7 was only moderately increased in the plasma of
NPC patients by comparison with non-NPC controls,
either healthy EBV-carriers or patients affected by non-
NPC tumors. More recently, Wong et al. have confirmed
the consistent detection of BART microRNAs in serum
samples from NPC patients suggesting a higher specificity
of detection for a sub-group of miR-BARTs including
miR-BART17-5p (hereafter called miR-BART17) [7].Therefore, we started this novel study with two aims: 1)
to substantiate the notion that miR-BART17 is detectable
with high specificity in plasma samples from NPC patients
of various geographic origins and 2) to better characterize
the vesicular or non-vesicular carriers of miR-BART17 in
human plasma. We report that miR-BART17 is detected
at a significantly higher concentration in the plasma of
NPC patients by comparison with non-NPC donors and
that its concentration is apparently not correlated to the
EBV DNA load. In addition, we provide substantial evi-
dence that circulating miR-BART17 molecules are associ-
ated with a protein-rich fraction of the plasma but not
with circulating exosomes.
Results
High concentrations of miR-BART17 in plasma samples
from NPC patients
We first evaluated by RT-qPCR ebv-miR-BART17-5p
(miR-BART17) and two cellular microRNAs - hsa-miR-
146a and hsa-miR-16 - in a pilot series of plasma sam-
ples from 3 NPC patients and 2 control donors bearing
non-NPC tumors (Figure 1). A synthetic microRNA
from Caenorhabditis Elegans, cel-miR-39, was used as
an exogenous control (it has no homology with mamma-
lian microRNAs). The same amount of cel-miR-39 was
“spiked-in” in all plasma samples at an early stage of
RNA extraction in order to monitor RNA extraction
bias. Hsa-miR-146a and hsa-miR-16 were used as en-
dogenous references. They are known to be abundant in
plasma samples from most human subjects although
with wide inter-individual variations [8]. As shown in
Figure 1, cel-miR-39 amplifications were homogeneous
in all five plasma samples, reflecting the good quality of
RNA extraction. As expected, amplifications of miR-
146a and miR-16 were heterogeneous but without spe-
cific distribution for the samples from NPC patients or
control donors. In contrast, significant amplifications of
miR-BART17 were only seen for NPC patients. There-
fore, we decided to extend this series to 27 consecutive
NPC patients and 10 control donors (9 donors bearing
non-NPC tumors and 1 healthy EBV-carrier). NPC pa-
tients were of various ethnical origins with a majority
from North Africa. They presented either with localized
(from stage II to stage IV b; UICC 2009) or metastatic
disease at first occurrence or following a tumor relapse
(Table 1). Some NPC patients had treatment prior to
plasma sample collection but all of them had active disease
at the time of blood drawing. Average CT values of the en-
dogenous viral and cellular microRNAs (miR-BART17,
miR-16 and miR-146) were normalized according to the
CT values obtained for the exogenous control microRNA
(miR-cel-39) in order to avoid RNA extraction bias (one
NPC patient was thus excluded from the beginning be-





Figure 1 Specific amplification of miR-BART17 in plasma RNAs from NPC patients (pilot study). Concentrations of miR-BART17, miR-146a,
miR-16 and cel-miR-39 microRNAs were assessed by qRT-PCR in plasma RNAs from 3 NPC patients (8, 16, 17; blue) and 2 controls (patients C1,
C2 bearing non-NPC Head and Neck carcinomas; red). ΔRn stands for the magnitude of the fluorescent signal generated during the PCR at each time
point (with background correction). Hsa-miR-16 and hsa-miR-146a are two cellular microRNAs known to be abundant in most human plasma samples.
Cel-miR-39 is a Caenorhabditis Elegans microRNA without homology to mammalian microRNAs. A constant amount of a synthetic cel-miR-39
microRNA was added to each plasma sample at an early stage of the RNA extraction procedure, providing an exogenous control in order to detect
RNA extraction bias. Amplification curves for cel-miR-39 are homogeneous in all 5 samples confirming the quality of the RNA extraction procedures. In
contrast, the amplification curves are heterogeneous for hsa-miR-16 and has-miR-146 but without separation of samples from NPC patients and from
control donors. On the contrary, marked amplifications of miR-BART17 are only seen for samples from NPC patients.
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microRNAs were deduced from calibration curves made
with the corresponding synthetic purified microRNAs.
Plasma concentrations of miR-BART17 are presented in
Tables 1 (NPC patients) and 2 (control patients) along
with patients characteristics. Concentrations of other cir-
culating microRNAs are presented in Additional file 1:
Table S1. It is noteworthy that the range of circulatingmicroRNA concentrations (copy number/mL) was lo-
wer by several orders of magnitude for miR-BART17
compared to the cellular microRNAs. In summary, con-
centrations were in a range of 1 X 101 to 6 X 105 for miR-
BART17 in contrast to a range of 5 X 105 to 3 X 109 for
miR-16 and miR-146 (Additional file 1: Table S1). The me-
dian concentration of plasma miR-BART17 was about 100
times higher for NPC patients (3220 copies/ml) than for
Table 1 Clinico-pathological characteristics, viral DNA load and plasma concentration of miR-BART17 normalized with
miR-cel-39 for samples from NPC patients
Patient Gender/age Origin First occurrence
(FO) or Relapse(R)




1 M/59 France FO cT4N2M0 NKUC 1559 26
2 M/43 Morocco R rT0N0M1 NKUC 7065 148
3 M/55 Cambodia FO cT3N0M0 NKUC 28 1226
4 M/40 Algeria FO cT4N1M0 NKUC 325 8014
5 M/61 Algeria FO cT2N2M0 NKUC 466 279
6 M/47 China FO cT2N0M0 NKUC 0 4501
7 F/34 Sweden FO cT2N3aM1 NKUC 67 11087
8 F/47 Tunisia FO cT2N1M0 NKDC 0 739
9 M/40 North Africa FO cT1N3bM0 NKUC 40 8824
10 M/51 North Africa FO cT3N2M1 NKUC 1142 242506
11 M/41 Turkey R rTXN1M0 KSCC 79 128426
12 M/49 France FO cT3N1M0 NKUC 0 2725
13 M/65 France R rT2N3bM0 NKUC 0 448961
14 M/58 Tunisia FO* cT2N0M0 NKUC 351 589
15 M/41 Tunisia FO* cT3N2M0 NKUC 1475 4889
16 F/49 France FO cT2N2M0 NKUC 9 205985
17 F/39 Morocco FO cT4N1M0 NKUC 0 1080
18 M/62 Algeria R* rT4N0M0 NKUC 328 161
19 M/66 Algeria R rT0N2M0 NKUC 31 25788
20 M/47 Cameroon R rTXN2M1 NKUC 21 42
21 M/58 Cameroon R* cT2bN1M1 NKUC 8 3220
22 M/60 Morocco R rT1N2M0 NKUC 136 4401
23 M/59 Algeria R rT1NxM0 NKUC 0 2465
24 M/58 Algeria FO* cT1N3bM0 NKUC 20 11
25 F/40 France R rT0N0M1 NKUC 0 155002
26 M/61 Cameroon R* rT4N0M0 NKUC 0 19881
Samples were collected prior to any treatment (FO), without any treatment in the previous last 6 months (R) or from patients under chemotherapy or chemo-
radiotherapy (FO* and R*). All patients had active disease at the time of blood sample collection. NKUC: non keratinizing undifferentiated carcinoma; NKDC: non-
keratinizing differentiated carcinoma; KSCC: keratinizing squamous cell carcinoma.
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2) (Figure 2). For optimal separation of NPC patients from
control donors, a threshold of 506 copy/mL of plasma was
determined by a ROC curve analysis (AUC= 0.87)
providing a true positive rate (sensitivity) of 0.77 and a
false positive rate (1-specificity) of 0.10 (Figure 3 and
Additional file 2: Figure S1).Apparent lack of correlations between miR-BART17
concentrations and EBV-DNA loads in NPC plasma samples
We found no apparent relationships between the plasma
concentrations of miR-BART17 and the plasma EBV DNA
load (Figure 4). It is noteworthy that among 5 NPC patients
with more than 105 copies of miR-BART17 per mL, four
had less than 200 copies of EBV-DNA per mL. Our serieshad obviously too much heterogeneity to allow tentative
correlations between clinical parameters and miR-BART17
or EBV DNA copy numbers in plasma samples.Changes in plasma concentrations of miR-BART17
according to tumor evolution in one patient
One patient presented in Table 1 (NPC patient n°5) initially
classified as T2N2M0 experienced a dramatic tumor pro-
gression under therapy with rapidly growing nodal and dis-
tant metastases (Figure 5). We could obtain 3 sequential
plasma samples from this patient. (1, 7 and 19 weeks fol-
lowing the time of the diagnosis). Real time PCR analyses
were performed simultaneously on these 3 samples dem-
onstrating an exponential increase of miR-BART17 plasma
concentrations which accompanied the rapid expansion of
Table 2 Clinico-pathological characteristics, viral DNA load and plasma concentration of miR-BART17 normalized with











C1 M/54 Tunisia larynx T3N0M0 SCC 0 12
C2 M/53 Tunisia larynx T2N0M0 SCC 0 14
C3 M/59 France larynx T3N0M0 SCC 0 783
C4 F/60 France larynx T2N0M0 SCC 0 277
C5 M/55 France larynx T3N0M0 SCC 0 27
C6 M/448 France hypopharynx T3N0M0 SCC 0 30
C7 M/47 France larynx T3N0M0 SCC 0 174
C8 M/56 France no tumor na na 0 18
C9 F/226 France maxilary sinus T4N1M0 SCC 0 435
C10 M/52 France hypopharynx T3N2M0 SCC 0 54
SCC: squamous cell carcinoma. C8 was a healthy donor. All other plasma samples except C10 were collected prior to treatment from patients bearing Head and
Neck non-NPC carcinomas. The sample from patient C10 was collected under therapy.
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EBV DNA load from 2 555 to 466 396 copies/mL from
week 7 to 19.
Distribution of miR-BART17 and hsa-miR-16 among
plasma lipoproteins separated by isopycnic density
gradient ultracentrifugation
As shown in the Additional file 1: Table S1, concentra-
tions of plasma miR-BART17 are very low by compari-
son with the circulating cellular microRNAs, miR-16
and miR-146a. In order to increase the sensitivity and
specificity of miR-BART17 detection, we attempted to
identify specific carrier elements of this microRNA in
human plasma samples. According to previous reports,
plasma microRNAs can be associated with at least 4
types of plasma carriers: microvesicles, exosomes, high
density lipoproteins (HDL) and non-vesicular ribonu-
cleoprotein complexes often containing the argonaute
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Figure 2 Comparative distribution of miR-146a, miR-16 and miR-BART
Samples from 26 NPC patients were compared to samples from 10 control
and one healthy carrier. As shown in this Box Plot representation, micro-RN
(P) and control donors (C) only for miR-BART17 (Wilcoxon test). Error bars rrelationships between BART microRNAs and these vari-
ous types of potential plasma carriers, we chose an open
experimental approach allowing simultaneous assessment
of these various carriers, i.e. flotation of plasma elements
on a KBr gradient. This method is commonly used for
separation of plasma lipoproteins and is also appropriate
for exosome separation [9,10]. Plasma samples from 2
NPC patients were fractionated on KBr gradients. RNAs
were purified from several fractions evenly distributed
through the gradient (11 to 12 out of 29). Then miR-16
and miR-BART17 were quantified by qRT-PCR. Simultan-
eously, the fractions corresponding to the various types of
lipoproteins were identified by assessment of cholesterol
concentration in each fraction. Surprisingly, the cellular
and the viral microRNAs did not co-purify with the same
fractions (Figure 6). The miR-16 was recovered in two
peaks; one small peak centered on fraction 17 and one
bigger peak centered on fraction 22 (NPC patient n°19) or
23 (NPC patient n°5). In contrast, miR-BART17 wasp = 9.7 X 10-6
iR-16 ebv-miR-BART-17 
C P P 
17 in plasma samples from NPC patients and control donors.
s including 9 patients bearing non-NPC Head and Neck carcinomas
A concentrations are significantly different between NPC patients























Figure 3 Analysis of miR-BART17 distribution in plasma samples from NPC patients and control donors. Histogram distribution of miR-
BART17 copy numbers among NPC patients (blue bars) and controls (yellow bars) with their relation to the threshold of 506 copies/mL calculated
by ROC analysis (see Additionnal file 2: Figure S1).
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where most proteins were recovered, with the exception
of a very small amount detected in fraction 23 for one
donor (NPC patient n°5). Exosomes are known to have a
density of 1.15 g/mL to 1.19 g/mL and are expected to
float deeper than the HDL peak (1.06 to 1.13 g/mL) [9].
To confirm the identity of the fractions containing the
exosomes, several bottom fractions of the gradients were
analyzed by Western blot for detection of CD63, a clas-
sical exosome marker. Consistent with the known density
of exosomes most of the CD63 protein was detected in
fractions 22 and/or 23, very close to the highest peak of
miR-16, indicating that at least a fraction of miR-16 co-





























Figure 4 Comparative distribution of plasmatic EBV DNA load
and miR-BART17 copy numbers among NPC patients. The
numbers on the axes are for the EBV DNA (x axis) and miR-BART17
(y axis) copies per mL of plasma (logarithmic scales). The samples
from each NPC patient appear as diamond-shaped dots. The
horizontal dotted line represents the threshold of 506 copies per mL
defined by ROC analysis (see the legend of Figure 3). Five patients
(10, 11, 13, 16 and 25) have more than 105 copies of miR-BART17
per mL (dots with asterisks). Only one of them (patient 10) has an
EBV DNA load with more than 102 copies/mL (one dot on the upper
right of the graph marked with a red asterisk).Discussion
Investigations of circulating microRNAs in malignant
diseases is currently a very active field and a large
amount of data have already been published about this
subject [8,11-13]. One remarkable characteristic of circu-
lating microRNAs is their stability. To a large extent, it re-
sults from their association with various types of carriers.
Some of these carriers are vesicular with a relatively
large size; the two main categories are microvesicles
(100 nm to 1 μm in diameter) and exosomes (30 to 100
nm). There are also non-vesicular carriers of smaller
size like the HDL lipoproteins and non-lipid ribonu-
cleoprotein complexes which, to a large extent, remain
to be characterized [10,11,14,15].
NPC appears as a privileged model for investigations of
circulating tumor microRNAs for two reasons: 1) malig-
nant cells are latently infected by EBV in virtually all NPCs;
2) NPC cells have intense production of microRNAs from
the BART cluster in the absence of production from the
BHRF1 cluster [2,4,16]. It is not yet clear whether mir-
BARTs can be produced in the healthy EBV-carrier or out-
side tumor tissues in NPC patients. According to in vitro
models, latently infected B-cells are not expected to pro-
duce miR-BARTs but rather BHRF1 microRNAs [2,4,17].
It is known that the EBV lytic-replicative cycle is consist-
ently taking place in the epithelial cells of the oral cavity
(including tonsils and may be salivary glands) [18]. We do
not know yet whether these lytically infected epithelial cells
produce and release EBV miR-BARTs.
Our data were obtained from NPC plasma samples
mainly collected from patients born in France and North
Africa. They are consistent with the data reported by
Wong et al. in a series of serum samples from 15 Chinese
patients [7]. Presence of circulating miR-BART17 thus ap-
pears as a consistent feature of the disease, regardless of
patient origins. Although there are discussions on whether
use of serum or plasma samples is optimal for recovery of
circulating microRNAs, our detection of miR-BART17
from plasma samples was apparently as efficient as the de-
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Figure 5 Evolution of miR-BART17 concentrations in plasma samples from an NPC patient with rapid disease progression. Several
plasma samples were sequentially collected from the NPC patient n°5. Two of them were obtained prior to any treatment. The third one was
obtained 5 weeks after completion of chemoradiotherapy in a context of very rapid, quasi-immediate, metastatic relapse. This tumor was initally
localized (T2N2M0) but it was highly hypermetabolic as shown on the sagittal image of 18Fluoro Deoxyglucose Positron Emission Tomography
(FDG-PET) combined to the computed tomography (CT) scan (SUVmax = 30.9). Data from miR-BART17 PCR-amplification were normalized using
data from concomitant cel-miR-39 amplification. Relative amounts of miR-BART17 were calculated according to the 2-ΔCt method. Error bars refer
to standard deviations. In the final sample collected in the context of the metastatic relapse, the concentration of plasma miR-BART17 was more
than 100 times higher than in the initial sample.
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detect small amounts of miR-BART17 in plasma samples
from non-NPC donors. This might be due to the fact that
we took in account samples with very small concentra-
tions of microRNAs, namely those giving Ct values higher
than 35, whereas they are automatically classified as nega-
tive by many investigators. The presence of miR-BART17
in plasma samples from a few control donors might reflect
low-level production of miR-BARTs by non-malignant
cells for example in the oral cavity. This should not under-
mine the main conclusion of our study: detection of the
miR-BART17-5p above the threshold of 506 copies/mL
appears as a marker of NPC plasma samples with good
sensitivity (77%) and high specificity (90%).
To further improve the sensitivity and specificity of
miR-BART detection in plasma samples, we attempted
to characterize their carriers. On the basis of previous
results, we were assuming that there were carried by
NPC tumor exosomes [6]. However, fractionation of
plasma elements on a KBr gradient showed that the cel-
lular micro-RNA, miR-16, partially co-purified with
exosomes whereas miR-BART17 was recovered in a
completely distinct fraction. Although it has only been
observed for our two samples subjected to gradient frac-
tionation, this observation may be relevant to the design
of future studies. On the one hand, the lack of co-
purification of miR-BART17 with exosomes is surprisingsince we and others have shown that the BART
microRNAs are abundant in exosomes released by EBV-
infected cells in vitro [6,21]. On the other hand, it ap-
pears to be consistent with a recent report about liver
microRNAs [22]. This report shows that, depending on
physiological or pathological conditions, the same micro-
RNAs co-purify either with an exosome-rich or a
protein-rich fraction of the plasma. Therefore we should
consider the hypothesis that the miR-BARTs are secreted
in association with exosomes by NPC cells in vitro but
not in the tumor context in vivo. The concentration of
miR-BART17 at the bottom of the KBr gradient suggests
that it is associated with non-floating elements, probably
ribonucleoprotein complexes of small size and/or devoid
of lipids which remained to be characterized. Other groups
have reported incorporation of plasma microRNAs in non-
vesicular complexes containing the Agonaute 2 (ago2)
protein [14]. In future investigations, it will be interesting
to know whether plasma ribonucleoprotein complexes
containing miR-BART17 can be immunoprecipitated with
anti-ago2 antibodies.
Our series of NPC patients was obviously too hetero-
geneous to attempt correlations between the concentra-
tion of plasma miR-BART17 and clinical parameters.
However, we were able to collect sequential plasma sam-
ples for one patient (Patient n°5) who had a rapidly pro-
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Figure 6 Distribution of miR-BART 17 in plasma fractions obtained by flotation on a potassium bromide gradient. Three mL plasma
aliquots from 2 NPC patients (n°5 and 19) were fractionated as described in the Materials and Methods section. Top panels. Twenty nine fractions
were analyzed for their cholesterol (dotted black line) and protein (solid blue line) contents. From the top to the bottom of the gradient, three
major cholesterol peaks allow identification of fractions containing VLDL (<1.006 g/mL), LDL (1.019 to 1.063 g/mL) and HDL (1.06 to 1.13 g/mL).
Protein concentration was maximal at the bottom of the gradient. Within fractions 25 to 28, it goes above 1000 mg/100mL. Middle panels.
Concentrations of miR-16, miR-BART17 and cel-miR-39 were determined in 11 to 12 selected fractions evenly distributed through the gradient.
They are presented as the ratio of the number of microRNA copies contained in each fraction to the sum of the copies contained in all fractions.
MiR-16 is mainly distributed in 2 peaks: one small peak coincident with fraction 17 and one bigger peak coincident with the portion of the
gradient containing the exosomes. In contrast, miR-BART17 is recovered almost exclusively in the bottom fraction. Bottom panels. Detection of
the CD63 protein by Western blot analysis in a set of selected fractions. After long exposure, CD63 signals are detected in fractions 22 and 23
(NPC patient n°5, left panel) and fraction 22 (NPC patient n°19, right panel). The densities of these fractions are in the range classically attributed
to exosomes (1.15 to 1.19 g/mL).
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tumor progression. This suggests that the plasma con-
centration of miR-BART17 is related, at least in part, to
the tumor mass. That point will require further investi-
gations. In this small series, we have found no obvious
correlations between the concentrations of plasma miR-
BART17 and the plasma EBV DNA loads. One can
speculate that both miR-BART and EBV DNA plasma
copy numbers are affected by multiple factors: the total
tumor burden, the apoptotic index of the malignant
cells, their rate of necrosis, the vascularization of tumorlesions and the rate of degradation of microRNAs and
DNA by peripheral nucleases. However, the relative im-
pact of each of these factors is probably different for the
miR-BARTs and for the EBV-DNA. This could explain
why their plasma concentrations might evolve independ-
ently at various stages of the disease. On the other hand,
if the concentrations of miR-BARTs and EBV DNA are
at least partially independent, they have more chances to
provide non-redundant information for assessment of
the tumor status and/or prediction of the tumor evolu-
tion. In order to substantiate this hypothesis, we currently
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circulating miR-BARTs and the total tumor mass in a series
of non-metastatic NPC patients; 2) the longitudinal evolu-
tion of circulating miR-BARTs in connection with the
tumor response to the initial treatment. While this study
was near completion, Chan et al. have reported a consistent
detection of miR-BART7 in the plasma of NPC patients
[23]. Both studies converge on two important points: 1)
EBV BART microRNAs are detectable in the plasma of
some non-NPC donors but at a low level in contrast with
most NPC patients; 2) the concentration of circulating
miR-BARTs seems to be relatively independent of the
plasma viral DNA load.Conclusions
This study confirms the consistent and specific presence
of a circulating miR-BART in plasma samples from NPC
patients. We provide evidence that the concentration of
plasma miR-BART17 is, at least in part, independent of
the plasma viral DNA load. In addition, we show that this
microRNA is not bound to plasma exosomes but probably
associated to non-vesicular ribonucleoprotein complexes.
These observations will provide a basis to address ques-
tions about the relationship of plasma miR-BARTs with
NPC volumetric characteristics and about their possible
role in the prediction of tumor response under treatment.Materials and methods
Collection, separation and storage of human plasma
samples
This study was performed with the approval of the Tarnier-
Cochin Ethics Committee (project n° 2746 approved on
January 27, 2010). Blood samples from 36 donors were col-
lected after signature of written informed consent, from June
2010 to October 2011. Twenty six of these samples were col-
lected from NPC patients admitted to the Institut de
Cancérologie Gustave Roussy or Paris hospitals working in
collaboration with this Institute (Table 1). All these patients
had evidence of active disease, either as a first occurrence or
as a recurrence. Blood samples were generally collected be-
fore initiation of the treatment (Table 1). Control samples
were obtained from 9 consecutive patients admitted to the
Department of Head and Neck Oncology at the Institut de
Cancérologie Gustave Roussy for non-NPC tumors. All
these tumors were squamous cell carcinomas of the upper
aero-digestive track. More clinical details are provided in
Table 2. One additional control plasma sample was
obtained from a healthy EBV-carrier donor. For all donors,
plasma was separated from blood collected in EDTA tubes
by centrifugation at 1700 g at 20°C for 15 min, aliquoted
and frozen at – 80°C. In virtually all cases, plasma separ-
ation and freezing was done in less than 2 hours following
blood collection.Clinical staging and pathological diagnosis
Tumor staging was performed according to UICC 7th edi-
tion (Union for International Cancer control) guidelines
[24]. Histological classification was performed according
to the 2005 WHO classification [25]. Except for 4 patients,
the histological diagnosis was confirmed by detection of
EBV products on tissue sections, either the LMP1 protein
detected by immunohistochemistry (3 cases) or the EBERs
(Epstein-Barr encoded RNAs) detected by in situ hyb-
ridization using commercial kits, mainly from Ventana
Medical System (Illkirch, France) [26].Isolation and chemical analysis of plasma lipoprotein
fractions
Plasma lipoproteins were isolated from 2 selected fasting
plasma samples (2 to 3 mL) by density gradient ultracentri-
fugation in a Beckman SW41 Ti rotor at 40 000 rpm for
42 hours in a Beckman XL70 at 15°C as previously de-
scribed [9]. Plasma density was increased to d=1.21 g/mL
by addition of dry, solid KBr. A discontinuous density gra-
dient was constructed as follows: 2 mL of NaCl-KBr solu-
tion of d=1.24 g/mL; 3 mL of plasma adjusted to a
background density of d=1.21 g/mL; 2 mL of d=1.063 g/
mL; 2.5 mL of d=1.019 g/mL; and finally, 2.5 mL of NaCl
solution of d=1.006 g/mL. After centrifugation, gradients
were collected from the top of the tubes with an Eppendorf
precision pipette in 30 fractions corresponding to VLDL
(density <1.006 g/mL, fraction number 1), IDL (density
from 1.006 g/mL to 1.019 g/mL, fraction number 2), 10
LDL subfractions (density from 1.019 g/mL to 1.063 g/mL,
fraction number 3 to 12) and 11 HDL subfractions (density
from 1.063 g/mL to 1.179 g/mL, fraction number 13 to
23). Lipoprotein fraction number 13 to 18 corresponded to
HDL2 fraction (density from 1.063 to 1.110 g/mL), lipopro-
tein fraction number 19 to 23 corresponded to HDL3 frac-
tion (density from 1.110 to 1.133 g/mL), and gradient
fraction numbers 24 to 30 mostly contain proteins. All
fractions were dialyzed in Spectropor membrane tubing
against Phosphate Buffer Saline at pH7.4 before analysis
for their content in total cholesterol using kit reagents
from Roche Diagnostics and in total protein using the
bicinchoninic acid assay from Pierce.RNA purification from plasma samples and use of
“spike-in” controls
Total RNA was purified using the miRVana PARIS kit
(Ambion, Austin, TX) according to the manufacturer in-
structions for total RNA purification from biological fluids.
At the beginning of the procedure, 300 μl of plasma were
mixed with 300 μl of 2X denaturing buffer and then incu-
bated for 10 minutes on ice. Just before the next step
which consisted in acid phenol/chloroform extraction, we
added to each sample a synthetic microRNA identical to
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RNA purification from fractions obtained after plasma
fractionation on KBr gadients
One hundred μl of each fraction (11 to 12 fractions out
of 29) were diluted in 200 μl of PBS 1X and then mixed
with 300 μl of 2X denaturing buffer. Total RNA was
then purified as described for crude plasma RNA.
CD63 detection by Western Blot after plasma
fractionation on KBr gradients
Four μg of protein were loaded on pre-casted, gradient
Acryl/BisAcryl 4-20% SDS gels purchased from Pierce
(Thermo Scientific, Brebières, France). Protein migration
and separation were performed in non-reducing condi-
tions to allow CD63 detection. CD63 was detected with
a mouse monoclonal antibody (TS63) kindly provided by
Eric Rubinstein [27].Determination of the EBV DNA load in plasma samples
Total DNA was extracted from 200 μl plasma aliquots
using the QIAmp blood DNA Minikit (Qiagen Inc.,
Courtaboeuf, France). Viral load was then determined by
real-time quantitative PCR using a commercial kit from
Argene (EBV R-gene™; France). The copy number of
EBV DNA per milliliter of plasma was determined using
a calibration curve based on serial dilutions of a stand-
ard provided in the kit. To rule out DNA extraction bias,
albumin DNA copies were quantified in parallel in the
same extracts as previously described [28].
MicroRNA amplification, detection and quantification by
quantitative RT-PCR
Real time RT-PCR analysis of the microRNAs was
performed using the Taqman MicroRNA Reverse Tran-
scription Kit and the Taqman MicroRNA Assay (Applied
Biosystems, Foster City, CA). For reverse transcription,
5.84 μl of a mix containing 3 μl of the RT primer solution
(final concentration: 50 nM ), 0.15 μl dNTP (1 mM), 1 μl
Multiscribe Reverse Transcriptase (3.33 U/μl), 1.50 μl of
10X Buffer and 0.19 μl RNase inhibitor (0.25 U/μl) were
added to 9.16 μl of plasma RNA (final volume: 15 μl). The
mix was then incubated successively at 16°C for 30
minutes, 42°C for 30 min and 85°C for 5 min. After reverse
transcription, PCR amplification was performed in 20 μl
containing 4 μl of the final Reverse Transcription reac-
tion mix mixed with 10 μl of FastStart Universal Probe
Master mix (Roche diagnostics, Basel, Switzerland), 1 μl
of the primer mix including - for a given microRNA -
the universal reverse primer (0.7 μM), the specific primer
(1.5 μM) and the hydrolysis probe (0.2 μM) (Taqman
microRNA assay, Applied Biosystems) and 5 μl ofnuclease free water (Ambion, Austin, TX). The first
cycle included one step of 2 min at 50°C and one step of
10 minutes at 95°C. It was followed by 45 cycles includ-
ing one step of 15 sec at 95°C and one step of 60 sec at
60°C. Multiple negative water blanks were included
in every analysis. Amplification was performed in a
StepOnePlus Detection System (Applied Biosystems).
Absolute quantification of microRNAs was done by com-
parison with 10-fold serial dilutions of synthetic double-
strand oligonucleotides containing the same sequences
(Eurofins MWG Operon, Ebersberg, Germany for ebv-
miR-BART17-5p and cel-miR-39 and miRVana miRNA
reference Panel v9.1, Ambion for hsa-miR-16a and hsa-
miR-146a). The concentration of the first dilution was 0.2
fmol/μl. The following sets of primers and probes were pur-
chased from Applied Biosystems (TaqMan MicroRNA as-
says): ebv-miR-BART17-5p (assay ID 008216), hsa-miR-16
(000391), hsa-miR-146a (000468) and cel-miR-39 (000200).
Calculation of the average “Concentration threshold” (Ct)
values from the triplicate was normalized to cel-miR-39
according to the method described by Kroh et al. [29].
Statistical analysis
Subjects were divided into a "condition" present group,
including all patients with NPC and a "condition" absent
group which included control subjects. Wilcoxon test
was used to compare differences in plasma microRNA
ratios between the NPC group and the control group.
P-value < 0.05 was considered significant. Receiver-
operating-characteristic (ROC) curves and the area under
the ROC curve (AUC) were used to assess the feasibility
of using plasma miRNAs as diagnostic tools for detecting
NPC. The ROC curve, together with a good tradeoff be-
tween the true positive rate and the false positive rate was
used to determine the cutoff value for the concentrations
of plasma microRNAs. A centered and scaled Principal
Component Analysis (PCA) was performed to assess vari-
ability and the correlations in the multivariate dataset
containing clinicopathological characteristics of patients,
plasma miRNAs (miR-146, miR-16, miR-BART17) and the
viral load. All analyses were performed using the R soft-
ware for statistical analysis (R version 2.14.1).Additional files
Additional file 1: Table S1. EBV DNA and miR-copy numbers from
plasma samples of NPC patients and controls. (1) UICC staging is
specified only for patients with a first occurrence of NPC. (2) MicroRNA
and DNA concentrations are expressed in copy number/mL.
Additional file 2: Figure S1. Receiver-operating characteristic (ROC)
curve analysis for miR-BART 17 copy numbers in plasma samples from 26
NPC patients (see Table 1) compared to 10 controls (see Table 2). From
the ROC curve, the AUC (area under the curve) was calculated allowing
determination of a cut-off value at 506 copies per mL with a sensitivity of
77% and a specificity of 90%.
Gourzones et al. Virology Journal 2013, 10:119 Page 11 of 12
http://www.virologyj.com/content/10/1/119Abbreviations
AUC: Area under curve; EBERs: Epstein-Barr encoded RNAs; EBV: Epstein Barr
virus; HDL: High density lipoprotein; LDL: Low density lipoprotein;
LMP1: Latent membrane protein1; NPC: Nasopharyngeal carcinoma;
ROC: Receiver-operating-characteristic; UICC: Union for International Cancer
control; VLDL: Very low density lipoprotein; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CG and FRF made RNA and c-DNA preparations and PCR analyses. They
were involved in the design of the study and preparation of the manuscript.
FRF, JG, BV, PL, FG, JK and ABC participated in sample collection and their
clinical annotation as well as separation and storage of several plasma
samples. ASJ and AG participated in the separation and storage of the
plasma samples and in RNA extraction. CHG shared his expertise for
handling qPCR on microRNAs. CA and VS have assayed the viral DNA load in
plasma samples. MG has done plasma fractionations on KBr gradients. AB
participated in the statistical analysis. PB participated in the design of the
study and its coordination and drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported by grants from the Gustave Roussy Foundation
(Head and Neck tumors – 2011), the Institut National du Cancer (INCa-DHOS
translational grant) and the Ligue Nationale contre le Cancer (comité du Val
de Marne). CG was supported by the Association pour la Recherche sur le
Cancer. Thanks are also due to the Commission Scientifique des Essais
Thérapeutiques and the Centre de Ressources Biologiques of the Institut de
Cancérologie Gustave Roussy for their help in the collection of clinical
samples.
Author details
1Université Paris-Sud 11, CNRS-UMR 8126 and Institut de Cancérologie
Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France. 2Ecole du
Val de Grâce, 1 place Alphonse Laveran, Paris 75005, France. 3Virology
Department, Hôpital Tenon, 4 rue de la Chine, Paris 75020, France. 4Head
and Neck Department, Hôpital Lariboisière, 2 rue Ambroise Paré, Paris 75010,
France. 5INSERM UMRS 939 - Université Pierre et Marie Curie - Paris6, Hôpital
de la Pitié, 83 boulevard de l’Hôpital, Paris 75013, France. 6Clinical Biology
Department, Institut Salah Azaiz, Tunis, Tunisia. 7Head and Neck Tumors
Department, Institut de Cancérologie Gustave Roussy, 39 rue Camille
Desmoulins, Villejuif 94805, France. 8Radiotherapy Department, Hôpital Pitié-
Salpétrière, 47 Boulevard de l’hôpital, Paris 75013, France.
Received: 29 November 2012 Accepted: 2 April 2013
Published: 16 April 2013
References
1. Feng BJ: Descriptive, environmental and genetic epidemiology of
nasopharyngeal carcinoma. In Nasopharyngeal carcinoma: Keys for
Translational Medicine and Biology. Edited by Bussson P. Austin and New-
York: Landes and Springer; 2012:23–41. [Back N, Cohen IR, Lajtha A, Lambris
JD, Paoletti R (Series Editor): Advances in Experimental Medicine and Biology].
2. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N,
Cullen BR: Epstein-Barr virus microRNAs are evolutionarily conserved and
differentially expressed. PLoS Pathog 2006, 2:e23.
3. Edwards RH, Marquitz AR, Raab-Traub N: Epstein-Barr virus BART
microRNAs are produced from a large intron prior to splicing. J Virol
2008, 82:9094–9106.
4. Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, Middeldorp J,
Thorley-Lawson DA: Comprehensive profiling of Epstein-Barr virus
microRNAs in nasopharyngeal carcinoma. J Virol 2009, 83:2357–2367.
5. Zhu JY, Pfuhl T, Motsch N, Barth S, Nicholls J, Grasser F, Meister G:
Identification of novel Epstein-Barr virus microRNA genes from
nasopharyngeal carcinomas. J Virol 2009, 83:3333–3341.
6. Gourzones C, Gelin A, Bombik I, Klibi J, Verillaud B, Guigay J, Lang P, Temam
S, Schneider V, Amiel C, et al: Extra-cellular release and blood diffusion of
BART viral micro-RNAs produced by EBV-infected nasopharyngeal
carcinoma cells. Virol J 2010, 7:271.7. Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY: Profiling of Epstein-
Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals
potential biomarkers and oncomirs. Cancer 2012, 118:698–710.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan
EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating
microRNAs as stable blood-based markers for cancer detection.
Proc Natl Acad Sci U S A 2008, 105:10513–10518.
9. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant
activity of tissue factor pathway inhibitor in human plasma is
preferentially associated with dense subspecies of LDL and HDL and
with Lp(a). Arteriosclerosis and thrombosis: a journal of vascular biology/
American Heart Association 1993, 13:1066–1075.
10. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT:
MicroRNAs are transported in plasma and delivered to recipient cells by
high-density lipoproteins. Nature cell biology 2011, 13:423–433.
11. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA:
MicroRNAs in body fluids–the mix of hormones and biomarkers. Nature
reviews Clinical oncology 2011, 8:467–477.
12. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ: Systemic
mirnas as potential biomarkers for malignancy. International journal of
cancer Journal international du cancer 2012, 131:2215–2222.
13. Cortez MA, Welsh JW, Calin GA: Circulating microRNAs as noninvasive
biomarkers in breast cancer. Recent results in cancer research Fortschritte der
Krebsforschung Progres dans les recherches sur le cancer 2012, 195:151–161.
14. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS,
Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al: Argonaute2
complexes carry a population of circulating microRNAs independent of
vesicles in human plasma. Proc Natl Acad Sci U S A 2011,
108:5003–5008.
15. Turchinovich A, Weiz L, Langheinz A, Burwinkel B: Characterization of
extracellular circulating microRNA. Nucleic Acids Res 2011, 39:7223–7233.
16. Gourzones C, Busson P, Raab-Traub N: Epstein-Barr Virus and the
Pathogenesis of Nasopharyngeal Carcinomas. In Nasopharyngeal Carcinoma:
Keys for Translational Medicine and Biology. Edited by Busson P. Austin/New-
York: Landes/Springer; 2012:42–60. [Back N, Cohen IR, Lajtha A, Lambris JD,
Paoletti R (Series Editor): Advances in Experimental Medicine and Biology].
17. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B: The microRNAs of
Epstein-Barr Virus are expressed at dramatically differing levels among
cell lines. Virology 2009, 386:387–397.
18. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA: The dynamics of EBV
shedding implicate a central role for epithelial cells in amplifying viral
output. PLoS pathogens 2009, 5:e1000496.
19. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ: Comparing the
MicroRNA spectrum between serum and plasma. PLoS One 2012, 7:e41561.
20. Gourzones C, Jimenez AS, Busson P: Profiling of Epstein-Barr virus-
encoded microRNAs in nasopharyngeal carcinoma reveals potential
biomarkers and oncomirs. Cancer 2012, 118:4634. author reply 4634–4635.
21. Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N:
Human tumor virus utilizes exosomes for intercellular communication.
Proc Natl Acad Sci U S A 2010, 107:20370–20375.
22. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K,
Szabo G: Circulating microRNAs in exosomes indicate hepatocyte injury
and inflammation in alcoholic, drug-induced, and inflammatory liver
diseases. Hepatology 2012, 56:1946–57.
23. Chan JY, Gao W, Ho WK, Wei WI, Wong TS: Overexpression of Epstein-Barr
virus-encoded microRNA-BART7 in undifferentiated nasopharyngeal
carcinoma. Anticancer Res 2012, 32:3201–3210.
24. Chan AT, Felip E: Nasopharyngeal cancer: ESMO clinical
recommendations for diagnosis, treatment and follow-up.
Ann Oncol 2009, 20(Suppl 4):123–125.
25. Nicholls J, Niedobitek G: Histopathological diagnosis of nasopharyngeal
carcinoma - Looking beyond the blue book. In Nasopharyngeal carcinoma:
Keys for Translational Medicine and Biology. Edited by Busson P. Austin/New-
York: Landes/Springer; 2012:10–22 [Back N, Cohen IR, Lajtha A, Lambris JD,
Paoletti R (Series Editor): Advances in Experimental Medicine and Biology].
26. Gourzones C, Ferrand FR, Vérillaud B, Busson P: Biological tools for NPC
population screening and disease monitoring. In Nasopharyngeal
Carcinoma: Keys for Translational Medicine and Biology. Edited by Busson P.
Austin and New-York: Landes and Springer; 2012:101–117 [Back N, Cohen
IR, Lajtha A, Lambris JD, Paoletti R (Series Editor): Advances in Experimental
Medicine and Biology].
Gourzones et al. Virology Journal 2013, 10:119 Page 12 of 12
http://www.virologyj.com/content/10/1/11927. Charrin S, Le Naour F, Oualid M, Billard M, Faure G, Hanash SM, Boucheix C,
Rubinstein E: The major CD9 and CD81 molecular partner. Identification
and characterization of the complexes. J Biol Chem 2001,
276:14329–14337.
28. Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M, Garbarg-
Chenon A, Nicolas JC: Quantification of Epstein-Barr virus load in
peripheral blood of human immunodeficiency virus-infected patients
using real-time PCR. J Med Virol 2001, 65:543–552.
29. Kroh EM, Parkin RK, Mitchell PS, Tewari M: Analysis of circulating microRNA
biomarkers in plasma and serum using quantitative reverse
transcription-PCR (qRT-PCR). Methods 2010, 50:298–301.
doi:10.1186/1743-422X-10-119
Cite this article as: Gourzones et al.: Consistent high concentration of
the viral microRNA BART17 in plasma samples from nasopharyngeal
carcinoma patients - evidence of non-exosomal transport. Virology
Journal 2013 10:119.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
